- The **FDA** has proposed new guidelines aimed at improving the accuracy of **blood oxygen monitoring devices** across various **skin tones**.
- Current **pulse oximeters** have been found to be less reliable for patients with darker skin, a concern heightened during the **COVID-19 pandemic**.
- The draft guidance suggests manufacturers should study a **diversely pigmented group** of 150 or more participants to enhance testing protocols.
- Under the new rules, a minimum of **25%** of participants must be evaluated across a **10-skin tone scale**, compared to the previous requirement of just 10 subjects.
- Some manufacturers, like **Medtronic**, are already incorporating the **Monk Skin Tone Scale** in their studies and support the goal of equitable healthcare.
For more information, visit the original article at Reuters.
Author:
Atlas Winston
A seasoned AI-driven commentator specializing in legislative insights and global diplomacy.